Treatment of psychiatric disturbances in hypokinetic movement disorders

References

• Hughes AJ, Daniel SE, Ben-Shlomo Y, et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125:861–870.
   PubMed Web of Science ®Google Scholar
• Belvisi D, Berardelli I, Suppa A, et al. Neuropsychiatric disturbances in atypical parkinsonian disorders. Neuropsychiatr Dis Treat. 2018;14:2643–2656.
   PubMed Web of Science ®Google Scholar
• Akbar U, Friedman JH. Recognition and treatment of neuropsychiatric disturbances in Parkinson’s disease. Exp Rev Neurother. 2015;15(9):1053–1065.
   PubMed Web of Science ®Google Scholar
• DeLong M, Wichmann T. Update on models of basal ganglia function and dysfunction. Parkinsonism Relat Disord. 2009;15(Suppl 3):S237–40.
   PubMedGoogle Scholar
• Pagonabarraga J, Kulivesky J, Strafella AP, et al. Apathy in Parkinson’s disease: clinical features, neural substrates, diagnosis and treatment. Lancet Neurol. 2015;14:518–531.
   PubMed Web of Science ®Google Scholar
• Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(03):S42–S80.
   PubMedGoogle Scholar
• Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019;34(2):180–198.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Stern MB. Intervening in the neuropsychiatric features of Parkinson’s disease. Exp Rev Neurother. 2007;7(6):699–710.
   PubMedGoogle Scholar
• Goldman JG, Holden M. Treatment of Psychosis and Dementia in Parkinson’s disease. Curr Treat Options Neurol. 2014;16:281-299.
   Web of Science ®Google Scholar
• Shotbolt P, Samuel M, Anthony D. Psychosis in Parkinson’s disease: how should we treat it? Exp Rev Neurother. 2006;6:1243–1246.
   PubMed Web of Science ®Google Scholar
• Samuel M, Rodriguez-Oroz M, Antonini A, et al. Management of impulse control disorders in Parkinson’s Disease: controversies and future approaches. Mov Disord. 2015;30:150–159.
   PubMed Web of Science ®Google Scholar
• Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24:1641–1649.
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Sullivan KL, Hauser RA. Nonmotor symptoms of Parkinson’s disease. Exp Rev Neurother. 2006 Dec 6;6(12):1811–1822.
   PubMedGoogle Scholar
• Hussl A, Seppi K, Poewe W. Nonmotor symptoms in Parkinson’s disease. Exp Rev Neurother. 2013;13:581–583.
   PubMed Web of Science ®Google Scholar
• Rana AQ, Ahmed US, Chaudry ZM, et al. Parkinson’s disease: a review of non-motor symptoms. Exp Rev Neurother. 2015;15:549–562.
   PubMed Web of Science ®Google Scholar
• Tandberg E, Larsen JP, Aarsland D, et al. The occurrence of depression in Parkinson’s disease. A community-based study. Arch Neurol. 1996;53:175–179.
   PubMed Web of Science ®Google Scholar
• Slaughter JR, Slaughter KA, Nichols D, et al. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2001;13:187–196.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Pahlhagen S, Ballard CG, et al. Depression in Parkinson disease— epidemiology, mechanisms and management. Nat Rev Neurol. 2012;8:35–47.
   Web of Science ®Google Scholar
• Taylor AE, Saint-Cyr JA, Lang AE, et al. Parkinson’s disease and depression. A critical re-evaluation. Brain. 1986;109:279–292.
   PubMed Web of Science ®Google Scholar
• Huber SJ, Freidenberg DL, Paulson GW, et al. The pattern of depressive symptoms varies with progression of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1990;53(4):275–278.
   PubMed Web of Science ®Google Scholar
• Berardelli I, Belvisi D, Corigliano V, et al. Suicidal ideation, perceived disability, hopelessness and affective temperaments in patients affected by Parkinson’s disease. Int J Clin Pract. 2018 Oct 19:e13287. Epub ahead of print. DOI:10.1111/ijcp.13287
   PubMed Web of Science ®Google Scholar
• Belvisi D, Berardelli I, Ferrazzano G, et al. The clinical correlates of suicidal ideation in Parkinson’s disease. Parkinsonism Relat Disord. 2019 Mar 3:ii: S1353-8020(19)30093–8. Epub ahead of print. DOI: 10.1016/j.parkreldis.2019.02.047
   Google Scholar
• Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573–580.
   PubMed Web of Science ®Google Scholar
• Barone P, Scarzella L, Marconi MA, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease. A national multicenter parallel-group randomized study. J Neurol. 2006;253:601–607.
   PubMed Web of Science ®Google Scholar
• Lemke MR, Brecht HM, Koester J, et al. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson disease. J Neurol Sci. 2006;248:266–270.
   PubMed Web of Science ®Google Scholar
• Barone P, Santangelo G, Morgante L, et al. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients. Eur J Neurol. 2015;22(8):1184–1191.
   PubMed Web of Science ®Google Scholar
• Chung SJ, Asgharnejad M, Bauer L, et al. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson’s disease. Expert Opin Pharmacother. 2016;17(11):1453–1461.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Taraborelli D, Morales KH. Escitalopram for major depression in Parkinson’s Disease: an open-label, flexible-dosage study. J Neuropsychiatry Clin Neurosci. 2006;18(3):377–383.
   PubMed Web of Science ®Google Scholar
• Menza M, Marin H, Kaufman K, et al. Citalopram treatment of depression in parkinson’s disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci. 2004;16:315–319.
   PubMed Web of Science ®Google Scholar
• Dell’Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson’s Disease: evidence from an open-label, prospective study. Clin Neuropharmacol. 2001;24(4):221–227.
   PubMed Web of Science ®Google Scholar
• Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology. 2000;55:1216–1218.
   PubMed Web of Science ®Google Scholar
• Tesei S, Antonini A, Canesi M, et al. Tolerability of paroxetine in Parkinson’s disease: a prospective study. Mov Disord. 2000;15:986–989.
   PubMed Web of Science ®Google Scholar
• Marino S, Sessa E, Di Lorenzo G, et al. Sertraline in the treatment of depressive disorders in patients with Parkinson’s disease. Neurol Sci. 2008;29:391–395.
   PubMed Web of Science ®Google Scholar
• Bonuccelli U, Meco G, Fabbrini G, et al. A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson’s disease. Expert Opin Pharmacother. 2012;13(16):2269–2280.
   PubMed Web of Science ®Google Scholar
• Avila A, Cardona X, Martin-Baranera M, et al. Agomelatine for depression in parkinson disease. Additional effect on sleep and motor dysfunction. J Clin Psychopharmacol. 2015;35:719–723.
   PubMed Web of Science ®Google Scholar
• Avila A, Cardona X, Martin-Baranera M, et al. Does nefazodone improve both depression and parkinson disease? A pilot randomized trial. J Clin Psychopharmacol. 2003;23:509–513.
   PubMed Web of Science ®Google Scholar
• Antonini A, Tesei S, Zecchinelli A, et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson’s disease and depression: effect on quality of life. Mov Disord. 2006;21(8):1119–1122.
   PubMed Web of Science ®Google Scholar
• Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009;72;886-892.
   Web of Science ®Google Scholar
• Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008;23(6):850–857.
   PubMed Web of Science ®Google Scholar
• Richard IH, McDermott MH, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78:1229–1236.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75:448–455.
   PubMed Web of Science ®Google Scholar
• Zhuo C, Xue R, Luo L, et al. Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis. Medicine (Baltimore). 2017 96;22(e6698):1–11.
   Google Scholar
• Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med. 2003;349:1925–1934.
   PubMed Web of Science ®Google Scholar
• Funkiewiez A, Ardouin C, Cools R, et al. Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson’s disease. Mov Disord. 2006;21:1656–1662.
   PubMedGoogle Scholar
• Castelli L, Zibetti M, Rizzi L, et al. Neuropsychiatric symptoms three years after subthalamic DBS in PD patients: a case-control study. J Neurol. 2008;255:1515–1520.
   PubMed Web of Science ®Google Scholar
• Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomised, multicentre study. Lancet Neurol. 2008;7:605–614.
   PubMed Web of Science ®Google Scholar
• Strutt AM, Simpson R, Jankovic J, et al. Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson’s disease. Eur J Neurol. 2012;19:121–127.
   PubMed Web of Science ®Google Scholar
• Lhommee E, Woitecki L, Czernecki V, et al. Behavioral outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson’s disease with early motor complications (EARLYSTIM trial): secondary analysis of an open label randomized trial. Lancet Neurol. 2018;17:223–231.
   PubMed Web of Science ®Google Scholar
• Okun MS, Fernandez HH, Wu SS, et al. Cognition and mood in Parkinson’s disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol. 2009;65:586–595.
   PubMed Web of Science ®Google Scholar
• Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2010;362:2077–2091.
   PubMed Web of Science ®Google Scholar
• Weaver FM, Follett KA, Stern M, et al. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology. 2012;79:55–65.
   PubMed Web of Science ®Google Scholar
• Moum SJ, Price CC, Limotai N, et al. Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One. 2012;7(1):e29768. Epub 2012 Jan 25.
   PubMed Web of Science ®Google Scholar
• Odekerken VJ, van Laar T, Staal MJ, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson’s disease (NSTAPS study): a randomised controlled trial. Lancet Neurol. 2013;12:37–44.
   PubMed Web of Science ®Google Scholar
• Boel JA, Oderkerken VJ, BA S, et al. Cognitive and psychiatric outcome 3 years after globus pallidus pars interna or subthalamic nucleus stimulation. Parkinsonism Relat Disord. 2016;33:90–95.
   PubMed Web of Science ®Google Scholar
• Brys M, Fox MD, Agarwal S, et al. Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: a randomized trial. Neurology. 2016;87(18):1907–1915.
   PubMed Web of Science ®Google Scholar
• Makkos A, Pál E, Aschermann Z, et al. High-frequency repetitive transcranial magnetic stimulation can improve depression in Parkinson’s disease: a randomized, double-blind, placebo-controlled study. Neuropsychobiology. 2016;73(3):169–177.
   PubMed Web of Science ®Google Scholar
• Dobkin RD, Allen LA, Menza M. Cognitive-behavioral therapy for depression in Parkinson’s disease: a pilot study. Mov Disord. 2007;22:946–952.
   PubMed Web of Science ®Google Scholar
• Dobkin RD, Allen LA, Menza M. A cognitive-behavioral treatment package for depression in Parkinson’s disease. Psychosomatics. 2006;47:259–263.
   PubMed Web of Science ®Google Scholar
• Cole K, Vaughan F. Brief cognitive behavioural therapy for depression associated with Parkinson’s disease: a single case series. Behav Cogn Psychother. 2005;33:89–102.
   Web of Science ®Google Scholar
• Feeney F, Egan S, Gasson N. Treatment of depression and anxiety in Parkinson’s disease: a pilot study using group cognitive behavioural therapy. Clin Psychol. 2005;9:31–38.
   Google Scholar
• Farabaugh A, Locascio JJ, Yap L, et al. Cognitive-behavioral therapy for patients with Parkinson’s disease and comorbid major depressive disorder. Psychosomatics. 2010;51:124–129.
   PubMed Web of Science ®Google Scholar
• Dobkin RD, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am J Psychiatry. 2011;168:1066–1074.
   PubMed Web of Science ®Google Scholar
• Dobkin RD, Mann SL, Interian A, et al. Cognitive behavioral therapy improves diverse profiles of depressive symptoms in Parkinson’s disease. Int J Geriatr Psychiatry. 2019;34:722–729.
   PubMed Web of Science ®Google Scholar
• Berardelli I, Pasquini M, Bloise M, et al. CBT Group intervention for depression, anxiety and motor symptoms in Parkinson’s disease: preliminary findings. Int J Cogn Ther. 2015;8(1):11–20.
   Web of Science ®Google Scholar
• Troeung L, Egan SJ, Gasson N. A waitlist-controlled trial of group cognitive behavioral therapy for depression and anxiety in Parkinson’s disease. BMC Psychiatry. 2014;27:14–19.
   Google Scholar
• Berardelli I, Bloise MC, Bologna M, et al. Cognitive behavioral group therapy versus psychoeducational intervention in Parkinson’s disease. Neuropsychiatr Dis Treat. 2018;14:399–405.
   PubMed Web of Science ®Google Scholar
• Dobkin RD, Menza M, Allen LA, et al. Telephone-based cognitive behavioral therapy for depression in Parkinson disease. J Geriatr Psychiatry Neurol. 2011;24:206–214.
   PubMed Web of Science ®Google Scholar
• Veazey C, Cook KF, Stanley M, et al. Telephone-administered cognitive behavioral therapy: a case study of anxiety and depression in Parkinson’s disease. J Clin Psychol Med Settings. 2009;16:243–253.
   PubMed Web of Science ®Google Scholar
• Wu PL, Lee M, Huang T. Effectiveness of physical activity on patients with depression and Parkinson’s disease: A systematic review. PLoS One. 2017 Jul 27;12(7):e0181515. eCollection 2017. .
   PubMed Web of Science ®Google Scholar
• Burini D, Farabollini B, Iacucci S, et al. A randomised controlled cross-over trial of aerobic training versus Qigong in advanced Parkinson’s disease. Eura Medicophys. 2006;42:231–238.
   PubMedGoogle Scholar
• Schmitz‐Hübsch T, Pyfer D, Kielwein K, et al. Qigong exercise for the symptoms of Parkinson’s disease: a randomized, controlled pilot study. Mov Disord. 2006;21(4):543–548.
   PubMed Web of Science ®Google Scholar
• Dereli EE, Yaliman A. Comparison of the effects of a physiotherapist-supervised exercise programme and a self-supervised exercise programme on quality of life in patients with Parkinson’s disease. Clin Rehab. 2010;24(4):352–362.
   PubMed Web of Science ®Google Scholar
• Smania N, Corato E, Tinazzi M, et al. Effect of balance training on postural instability in patients with idiopathic Parkinson’s disease. Neurorehabil Neural Repair. 2010;24(9):826–834.
   PubMed Web of Science ®Google Scholar
• Khallaf M, Fathy H. Effect of treadmill training on activities of daily living and depression in patients with Parkinson’s disease. Middle East Curr Psych. 2011;18(3):144–148.
   Google Scholar
• Altmann LJ, Stegemöller E, Hazamy AA, et al. Aerobic exercise improves mood, cognition, and language function in Parkinson’s disease: results of a controlled study. J Int Neuropsychol Soc. 2016;22(9):878–889.
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Ridgel AL, Walter EM, et al. A randomized trial of individual versus group-format exercise and self-management in individuals with Parkinson’s disease and comorbid depression. Patient Prefer Adherence. 2017;11:965–973.
   PubMed Web of Science ®Google Scholar
• Kwok JYY, Kwan JCY, Auyeung M, et al. The effects of yoga versus stretching and resistance training exercises on psychological distress for people with mild-to-moderate Parkinson’s disease: study protocol for a randomized controlled trial. Trials. 2017 Nov 2;18(1):509. .
   PubMedGoogle Scholar
• Cheon SM, Chae BK, Sung HR, et al. The efficacy of exercise programs for Parkinson’s disease: tai Chi versus combined exercise. J Clin Neurol. 2013;9(4):237–243.
   PubMed Web of Science ®Google Scholar
• Dashtipour K, Johnson E, Kani C, et al. Effect of exercise on motor and nonmotor symptoms of Parkinson’s disease. Parkinson’s Dis. 2015;2015(586378):1–5.
   Google Scholar
• Lee NY, Lee DK, Song HS. Effect of virtual reality dance exercise on the balance, activities of daily living, and depressive disorder status of Parkinson’s disease patients. J Phys Ther Sci. 2015;27(1):145–147.
   PubMedGoogle Scholar
• Sturkenboom IH, Hendriks JC, Graff MJ, et al. Efficacy of occupational therapy in Parkinson’s disease: a randomized controlled trial. Lancet Neurol. 2014;13:557–566.
   PubMed Web of Science ®Google Scholar
• Cristian A, Katz M, Cutrone E, et al. Evaluation of acupuncture in the treatment of Parkinson’s disease: a double-blind pilot study. Mov Disord. 2005;20(9):1185–1188.
   PubMed Web of Science ®Google Scholar
• Cho SY, Shim SR, Rhee HY, et al. Effectiveness of acupuncture and bee venom acupuncture in idiopathic Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(8):948–952.
   PubMed Web of Science ®Google Scholar
• Pacchetti C, Mancini F, Aglieri R, et al. Active music therapy in Parkinson’s disease: an integrative method for motor and emotional rehabilitation. Psychosom Med. 2000;62(3):386–393.
   PubMed Web of Science ®Google Scholar
• Modugno N, Iaconelli S, Fiorlli M, et al. Active theater as a complementary therapy for Parkinson’s disease rehabilitation: a pilot study. Scientific World J. 2010 Nov 16;10: 2301–2313. .
   Google Scholar
• Advocat J, Enticott J, Vandenberg B, et al. The effects of a mindfulness-based lifestyle programme for adults with Parkinson’s disease: protocol for a mixed methods, randomised two-group control study. BMC Neurol. 2016;16:166.
   PubMed Web of Science ®Google Scholar
• Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord. 2007 Jun 15;22(8):1061–1068.
   PubMed Web of Science ®Google Scholar
• Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology. 2003 10;60(11):1756–1761.
   PubMed Web of Science ®Google Scholar
• Barnes J, David AS. Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry. 2001;70(6):727–733.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Fan W, Leurgans S, et al. The malignant course of “benign hallucinations” in Parkinson’s disease. Arch Neurol. 2006;63(5):713–716.
   PubMedGoogle Scholar
• Poletti M, Perugi G, Logi C, et al. Dopamine agonists and delusional jealousy in Parkinson’s disease: a cross-sectional prevalence study. Mov Disord. 2012;27(13):1679–1682.
   PubMed Web of Science ®Google Scholar
• The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson’s disease. Lancet. 1999 12;353(9169):2041–2042.
   PubMed Web of Science ®Google Scholar
• The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999;340:757–763.
   PubMed Web of Science ®Google Scholar
• Ellis T, Cudkowicz ME, Sexton PM, et al. Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2000;12:364–369.
   PubMed Web of Science ®Google Scholar
• Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27:153–156.
   PubMed Web of Science ®Google Scholar
• Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689–695.
   PubMed Web of Science ®Google Scholar
• Merims D, Balas M, Peretz C, et al. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. Clin Neuropharmacol. 2006;26:331–337.
   Google Scholar
• Juncos JL, Roberts VJ, Evatt ML, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson’s disease. Mov Disord. 2004;19:29–35.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord. 2005;958–963.
   PubMed Web of Science ®Google Scholar
• Rabey JM, Prokhorov T, Miniovitz L, et al. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord. 2007;22:313–318.
   PubMed Web of Science ®Google Scholar
• Shotbolt P, Samuel M, Fox C, et al. A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease. Neuropsych Dis Treat. 2009;5:327–332.
   PubMed Web of Science ®Google Scholar
• Prohorov T, Klein C, Miniovitz A, et al. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. J Neurol. 2006;253:171–175.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine comparative effects on motor function in hallucinating PD patients. Neurology. 2000;55:789–794.
   PubMed Web of Science ®Google Scholar
• Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry. 2002;52:438–445.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;5:1031–1035.
   Google Scholar
• Go´mez-Esteban JC, Zarranz JJ, Velasco F, et al. Use of ziprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol. 2005;28:111–114.
   PubMed Web of Science ®Google Scholar
• Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s Disease. Mov Disord. 2006;21(12):2078–2081.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin (2A) receptor inverse agonist, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology. 2010;35(4):881–892.
   PubMed Web of Science ®Google Scholar
• Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomized, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–540.
   PubMed Web of Science ®Google Scholar
• Webster P. Pimavanserin evaluated by the FDA. Lancet. 2018;391(10132):1762.
   PubMed Web of Science ®Google Scholar
• Patel N, LeWitt P, Neikrug AB, et al. Nighttime and daytime sleepiness improved with pimavanserin during treatment of Parkinson’s disease psychosis. Clin Neuropharmacol. 2018;41(6):210–215.
   PubMed Web of Science ®Google Scholar
• Jethwa KD, Onalaja OA. Antipsychotics for the management of psychosis in Parkinson’s disease: systematic review and meta-analysis. BJPsych Open. 2015;1:27–33.
   PubMed Web of Science ®Google Scholar
• Iketani R, Yohei Kawasaki Y, Yamada H. Comparative utility of atypical antipsychotics for the treatment of psychosis in Parkinson’s disease: a systematic review and bayesian network meta-analysis. Biol Pharm Bull. 2017;40:1976–1982.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Claassen DO. Impulse control and related disorders in Parkinson’s disease. Int Rev Neurobiol. 2017;133:679–717.
   PubMed Web of Science ®Google Scholar
• Voon V, Napier TC, Frank MJ, et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson’s disease: an update. Lancet Neurol. 2017;16(3):238–250.
   PubMed Web of Science ®Google Scholar
• Vitale C, Amboni M, Erro R, et al. Parkinson’s disease management and impulse control disorders: current state and future perspectives. Exp Rev Neurother. 2019 Jun;19(6):495–508.
   PubMed Web of Science ®Google Scholar
• Thomas A, Bonanni L, Gambi F, et al. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. 2010;68:400–404.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Sohr M, Potenza MN, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross sectional study. Ann Neurol. 2010;68:963–968.
   PubMed Web of Science ®Google Scholar
• Rotondo A, Bosco D, Plastino M, et al. Clozapine for medication related pathological gambling in Parkinson disease. Mov Disord. 2010;25:1994–1995.
   PubMed Web of Science ®Google Scholar
• Ramirez-Zamora A, Gee L, Boyd J, et al. Treatment of impulse control disorders in Parkinson’s disease: practical considerations and future directions. Expert Rev Neurother. 2016;16(4):389–399.
   PubMed Web of Science ®Google Scholar
• Sevincok L, Akoglu A, Akyol A. Quetiapine in a case with Parkinson disease and pathological gambling. J Clin Psychopharmacol. 2007;27:107–108.
   PubMed Web of Science ®Google Scholar
• Papay K, Xie SX, Stern M, et al. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology. 2014;83:826–833.
   PubMed Web of Science ®Google Scholar
• Epstein J, Jimenez Madiedo C, Lai L, et al. Successful treatment of dopamine dysregulation syndrome with valproic acid. J Neuropsychiatry Clin Neurosci. 2014;26:3.
   Web of Science ®Google Scholar
• Sriram A, Ward EH, Hassan A, et al. Valproate as a treatment for dopamine dysregulation syndrome in Parkinson’s disease. J Neurol. 2013;260:521–527.
   PubMed Web of Science ®Google Scholar
• Hicks CW, Pandya MM, Itin I, et al. Vaproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson’s disease. Parkinsonism Relat Disord. 2011;17:379–381.
   PubMed Web of Science ®Google Scholar
• Lim SY, O’Sullivan SS, Kotschet K, et al. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson’s disease. J Clin Neurosci. 2009;16(9):1148–1152.
   PubMed Web of Science ®Google Scholar
• Kim YE, Kim HJ, Kim HJ, et al. Impulse control and related behaviors after bilateral subthalamic stimulation in patients with Parkinson’s disease. J Clin Neurosci. 2013;20(7):964–969.
   PubMed Web of Science ®Google Scholar
• Lhommee E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson’s disease: restoring the balance of motivated behaviours. Brain. 2012;135:1463–1477.
   PubMed Web of Science ®Google Scholar
• Amami P, Dekker I, Piacentini S, et al. Impulse control behaviours in patients with Parkinson’s disease after subthalamic deep brain stimulation: de novo cases and 3-year follow-up. J Neurol Neurosurg Psychiatry. 2015;86(5):562–564.
   PubMed Web of Science ®Google Scholar
• Gee L, Smith H, De La Cruz P, et al. The influence of bilateral subthalamic nucleus deep brain stimulation on impulsivity and prepulse inhibition in Parkinson’s disease patients. Stereotact Funct Neurosurg. 2015;93(4):265–270.
   PubMed Web of Science ®Google Scholar
• Merola A, Romagnolo A, Rizzi L, et al. Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease. J Neurol. 2017;264:40–48.
   PubMed Web of Science ®Google Scholar
• Rossi PJ, De Jesus S, Hess CW, et al. Measures of impulsivity in Parkinson’s disease decrease after DBS in the setting of stable dopamine therapy. Parkinsonism Relat Disord. 2017;44:13–17.
   PubMed Web of Science ®Google Scholar
• Abbes M, Lhommee E, Thobois S, et al. Subthalamic stimulation and neuropsychiatric symptoms in Parkinson’s disease: results from a long-term follow-up cohort study. J Neurol Neurosurg Psychiatry. 2018;89:836–843.
   PubMed Web of Science ®Google Scholar
• Kim A, Kim YE, Kim HJ, et al. A 7-year observation of the effect of subthalamic deep brain stimulation on impulse control disorders in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2018;56:3–8.
   PubMed Web of Science ®Google Scholar
• Jimenez-Murcia S, Bove FI, Israel M, et al. Cognitive-behavioral therapy for pathological gambling in Parkinson’s disease: a pilot-controlled study. Eur Addict Res. 2012;18:265–274.
   PubMed Web of Science ®Google Scholar
• Okai D, Askey-Jones S, Samuel M, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology. 2013;80:792–799.
   PubMed Web of Science ®Google Scholar
• Zhu K, van Hilten JJ, Marinus J. Onset and evolution of anxiety in Parkinson’s disease. Eur J Neurol. 2017;24:404–411.
   PubMed Web of Science ®Google Scholar
• Broen MPG, Narayen NE, Kuijf ML, et al. Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2016;31:1125–1133.
   PubMed Web of Science ®Google Scholar
• van der Velden RMJ, Broen MPG, Kuijf ML, et al. Frequency of mood and anxiety fluctuations in Parkinson’s disease patients with motor fluctuations: A systematic review. Mov Disord. 2018;33(10):1521–1527.
   PubMed Web of Science ®Google Scholar
• Ciurleo R, Corallo F, Bonanno L, et al. Assessment of Duodopa® effects on quality of life of patients with advanced Parkinson’s disease and their caregivers. J Neurol. 2018;265(9):2005–2014.
   PubMed Web of Science ®Google Scholar
• Berardelli I, Pasquini M, Roselli V, et al. Cognitive behavioral therapy in movement disorders: a review. Mov Disord Clin Pract. 2015 Jun 2;2(2):107–115. .
   PubMed Web of Science ®Google Scholar
• Martin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3:243–254.
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Lentjiens AF. The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatry. 2008;10:1088–1092.
   Google Scholar
• Liu J, Cooper CA, Weintraub D. Dahodwala. Pharmacological treatment of apathy in Lewy body disorder: a systematic review. Parkinsonism Relat Disord. 2019;60:14–24.
   PubMed Web of Science ®Google Scholar
• Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson’s disease. Clin Neuropharmacol. 1988;11:512–519.
   PubMed Web of Science ®Google Scholar
• Comella CL, Morissey M, Janko K. Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy. Neurology. 2005;64:1450–1451.
   PubMed Web of Science ®Google Scholar
• Dowling GA, Mastick J, Colling E, et al. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med. 2005;6:459–466.
   PubMed Web of Science ®Google Scholar
• Menza M, Dobkin RD, Marin H, et al. Treatment of insomnia in Parkinson’s disease: a controlled study of eszopiclone and placebo. Mov Disord. 2010;25:1708–1714.
   PubMed Web of Science ®Google Scholar
• Rios Romenets S, Creti L, Fichten C, et al. Doxepine and cognitive behavioral therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism Relat Disord. 2013;19:670–675.
   PubMed Web of Science ®Google Scholar
• Pan W, Kwak S, Li G, et al. Therapeutic effect of Yang-Xue-Qjng-Nao granules on sleep dysfunction in Parkinson disease. Chin Med. 2013;8:14.
   PubMed Web of Science ®Google Scholar
• Di Giacopo R, Fasano A, Quaranta D, et al. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson disease. Mov Disord. 2012;27:559–561.
   PubMed Web of Science ®Google Scholar
• Yang S, Sajatovic M, Walter BL. Psychosocial interventions for depression and anxiety in Parkinson’s disease. J Geriatr Psychiatry Neurol. 2012;25:113–121.
   PubMed Web of Science ®Google Scholar
• Rodriguez TM, Castro Caldas A, Ferreira JJ. Pharmacological interventions for daytime sleepiness and sleep disorders: systematic review and meta-analysis. Parkinsonism Relat Disord. 2016;7:25–34.
   Google Scholar
• Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson’s disease: a randomized controlled trial. Neurology. 2012;79:651–658.
   PubMed Web of Science ®Google Scholar
• Elbers RG, Verhoef J, vanWegen EE, et al. Interventions for fatigue in Parkinson’s disease. Cochrane Database Syst Rev. 2015 Oct 8;(10):CD010925. doi: 10.1002/14651858.CD010925.pub2.
   Web of Science ®Google Scholar
• Fabbrini G, La Torre A, Suppa A, et al. Fatigue in Parkinson’s disease: motor or non-motor symptom? Parkinsonism Rel Disord. 2013;19:148–152.
   PubMed Web of Science ®Google Scholar
• Schifitto G, Friedman JH, Oakes D, et al. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology. 2008 12;71(7):481–485.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Shinawi L, Davidson A, et al. Memantine for non-motor features of Parkinson’s disease: a double-blind placebo controlled exploratory pilot trial. Parkinsonism Relat Disord. 2011;17(3):156–159.
   PubMed Web of Science ®Google Scholar
• Mendonca MA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord. 2007;22(14):2070–2076.
   PubMed Web of Science ®Google Scholar
• Lou JS, Dimitrova DM, Park BS, et al. Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study. Clin Neuropharmacol. 2009;32(6):305–310.
   PubMed Web of Science ®Google Scholar
• Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011;10:415–423.
   PubMed Web of Science ®Google Scholar
• Lim TT, Kluger BM, Rodriguez RL, et al. Rasagiline for the symptomatic treatment of fatigue in Parkinson’s disease. Mov Disord. 2015;30:1825–1830.
   PubMed Web of Science ®Google Scholar
• Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008 26;71(9):670–676.
   PubMed Web of Science ®Google Scholar
• Benrud-Larson LM, Sandroni P, Schrag A, et al. Depressive symptoms and life satisfaction in patients with multiple system atrophy. Mov Disord. 2005;20(8):951–957.
   PubMed Web of Science ®Google Scholar
• Schrag A, Sheikh S, Quinn NP, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2010;25(8):1077–1081.
   PubMed Web of Science ®Google Scholar
• Fetoni V, Soliveri P, Monza D, et al. Affective symptoms in multiple system atrophy and Parkinson’s disease: response to levodopa therapy. J Neurol Neurosurg Psychiatry. 1999;66:541–544.
   PubMed Web of Science ®Google Scholar
• Colosimo C, Bak TH, Bologna M, et al. Fifty years of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2014;85:938–944.
   PubMed Web of Science ®Google Scholar
• Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord. 2017;32(6):853–864.
   PubMed Web of Science ®Google Scholar
• Litvan I, Mega MS, Cummings JL, et al. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology. 1996;47:1184–1189.
   PubMed Web of Science ®Google Scholar
• Bloise MC, Berardelli I, Roselli V, et al. Psychiatric disturbances in patients with progressive supranuclear palsy: A case-control study. Parkinsonism Rel Disord. 2014;20:965–968.
   PubMed Web of Science ®Google Scholar
• Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol. 1993;16:338–346.
   PubMed Web of Science ®Google Scholar
• Boulogne L, Le Camus F, Bation R, et al. Repetitive transcranial magnetic stimulation can alleviate treatment-resistant depression in patients with progressive supranuclear palsy. Parkinsonism Relat Disord. 2015;21(9):1113–1114.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Litvan I, Lang AE, et al. Criteria for corticobasal degeneration. Neurology. 2013;80(5):496–503.
   PubMed Web of Science ®Google Scholar
• Marsili L, Suppa A, Berardelli A, et al. Therapeutic interventions in corticobasal syndrome. Parkinsonism Relat Disord. 2016;22(Suppl 1):S96–100.
   PubMedGoogle Scholar
• Tarakita N, Nishijima K, Yasoui-Furukori N. Levodopa responsive depression associated with corticobasal degeneration: a case report. Neuropsychiatr Dis Treat. 2017 Apr;18(13):1107–1110.
   Google Scholar
• Hargrave R. Depression in corticobasal degeneration. Psychosomatics. 1998;39:481–482.
   PubMed Web of Science ®Google Scholar
• Boot BP. Comprehensive treatment of dementia with Lewy bodies. Alzheimers Res Ther. 2015;7:45.
   PubMed Web of Science ®Google Scholar
• McKeith IJ, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies. Fourth consensus report of the DLB Consortium. Neurology. 2017;89:1–13.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Ballard C, Rongve A, et al. Clinical trials of dementia with Lewy bodies and Parkinson’s disease dementia. Curr Neurol Neurosci Rep. 2012;12:492–501.
   PubMed Web of Science ®Google Scholar
• McKeith IG, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ. 1992;305:673–678.
   PubMed Web of Science ®Google Scholar
• Ballard C, Grace J, McKeith I, et al. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer’s disease. Lancet. 1998;351:1032–1033.
   PubMed Web of Science ®Google Scholar
• Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2002;13:67–73.
   PubMed Web of Science ®Google Scholar
• Kurlan R, Cummings J, Raman R, et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68:1356–1363.
   PubMed Web of Science ®Google Scholar
• Culo S, Mulsant BH, Rosen J, et al. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled trial. Alzheimer Dis Assoc Disord. 2010;24(4):360–364.
   PubMed Web of Science ®Google Scholar
• McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo controlled international study. Lancet. 2000;356:2031–2036.
   PubMed Web of Science ®Google Scholar
• Fasano A, Daniele A, Albanese A. Treatment of motor and non-motor features of Parkinson’s disease with deep brain stimulation. Lancet Neurol. 2012;11:429–442.
   PubMed Web of Science ®Google Scholar
• Romito LM, Raja M, Daniele A, et al. Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson’s disease. Mov Disord. 2002;17:1371–1374.
   PubMed Web of Science ®Google Scholar
• Kulisevsky J, Berthier ML, Gironell A, et al. Mania following deep brain stimulation for Parkinson’s disease. Neurology. 2002;59:1421–1424.
   PubMed Web of Science ®Google Scholar
• Ulla M, Thobois S, Lemaire JJ, et al. Manic behaviour induced by deep-brain stimulation in Parkinson’s disease: evidence of substantia nigra implication? J Neurol Neurosurg Psychiatry. 2006;77:1363–1366.
   PubMed Web of Science ®Google Scholar
• Bejjani BP, Damier P, Arnulf I, et al. Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med. 1999;340:1476–1780.
   PubMed Web of Science ®Google Scholar
• Tommasi G, Lanotte M, Albert U, et al. Transient acute depressive state induced by subthalamic region stimulation. J Neurol Sci. 2008;273:135–138.
   PubMed Web of Science ®Google Scholar
• Blomstedt P, Hariz MI, Lees A, et al. Acute severe depression induced by intraoperative stimulation of the substantia nigra: a case report. Parkinsonism Relat Disord. 2008;14:253–256.
   PubMed Web of Science ®Google Scholar
• Mosley PE, Smith D, Coyne T, et al. The site of stimulation moderates neuropsychiatric symptoms after subthalamic deep brain stimulation for Parkinson’s disease. Neuroimage Clin. 2018;18:996–1006.
   PubMed Web of Science ®Google Scholar
• Castrioto A, Lhommée E, Moro E, et al. Mood and behavioral effects of subthalamic stimulation in Parkinson’s disease. Lancet Neuro. 2014;13:287–305.
   PubMed Web of Science ®Google Scholar
• Dobkin RD, Menza M, Bienfait KL. CBT for the treatment of depression in Parkinson’s disease: a promising non pharmacological approach. Exp Rev Neurother. 2008;8:27–35.
   PubMedGoogle Scholar
• Berardelli I, Pasquini M, Roselli V, et al. Cognitive behavioral therapy in movement disorders: a review. Mov Disord Clin Pract. 2015;2:107–111.
   PubMed Web of Science ®Google Scholar
• Mulders AEP, Moonen AJH, Dujardin K, et al. Cognitive behavioural therapy for anxiety disorders in Parkinson’s disease: design of a randomised controlled trial to assess clinical effectiveness and changes in cerebral connectivity. J Psychosom Res. 2018;112:32–39.
   PubMed Web of Science ®Google Scholar
• Bega D, Zadikoff C. Complementary & alternative management of Parkinson’s Disease: an evidence-based review of eastern influenced practices. J Mov Disord. 2014 Oct;7(2):57–66.
   PubMedGoogle Scholar
• Lee HS, Park HL, Lee SJ, et al. Scalp acupuncture for Parkinson’s disease: a systematic review of randomized controlled trials. Chin J Integr Med. 2013 Apr;19(4):297–306.
   PubMed Web of Science ®Google Scholar
• Subramanian I. Complementary and alternative medicine and exercise in nonmotor symptoms of Parkinson’s Disease. Int Rev Neurobiol. 2017;134:1163–1188.
   PubMed Web of Science ®Google Scholar
• Šumec R, Filip P, Sheardová K, et al. Psychological benefits of nonpharmacological methods aimed for improving balance in Parkinson’s Disease: a systematic review. Behav Neurol. 2015;620674. Epub 2015 Jul 7. Review. DOI:10.1155/2015/620674
   PubMed Web of Science ®Google Scholar
• Elefant C, Baker FA, Lotan M, et al. The effect of group music therapy on mood, speech, and singing in individuals with Parkinson’s disease–a feasibility study. J Music Ther. 2012;49(3):278–302.
   PubMed Web of Science ®Google Scholar
• Kabra A, Sharma R, Kabra R, Baghel US. Emerging and alternative therapies for Parkinson disease: an updated review. Curr Pharm Des. 2018;24(22):2573–2582.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Donnelly EM, Friedman JH. Long-Term Outcome of Clozapine Use for Psychosis in Parkinsonian Patients. Mov Disord. 2004;19:829–862.
   PubMed Web of Science ®Google Scholar
• Hermanowicz S, Hermanowicz N. The safety, tolerability and efficacy of pimavamserin tartrate in the treatment of psychosis in Parkinson’s disease. Exp Rev Neurother. 2016;16:625–633.
   PubMed Web of Science ®Google Scholar
• Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann Neurol. 2011;69(6):986–996.
   PubMed Web of Science ®Google Scholar
• Ambermoon P, Carter A, Hall WD, et al. Impulse control disorders in patients with Parkinson’s disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction. 2011;106(2):283–293.
   PubMed Web of Science ®Google Scholar
• Calandrella D, Antonini A. Pathological gambling in Parkinson’s disease: disease-related or drug related? Exp Rev Neurother. 2011;11:809–814.
   PubMed Web of Science ®Google Scholar
• Ramirez-Zamora A, Gee L, Boyd J, et al. Treatment of impulse control disorders in Parkinson’s disease: practical considerations and future directions. Expert Rev Neurother. 2016;16(4):389–399.
   PubMed Web of Science ®Google Scholar
• Collerton D, Taylor JP. Advances in the treatment of visual hallucinations in neurodegenerative disorders. Future Neurol. 2013;8(4):433–444.
   PubMedGoogle Scholar
• Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012;3:CD006504.
   PubMed Web of Science ®Google Scholar